Johnson & Johnson’s Executive Vice President and CFO, Joseph J. Wolk, sold 84,654 shares of company stock for approximately $21.7 million and exercised options to acquire 66,475 shares. Following the transactions, Wolk directly owns 38,961 shares, with additional indirect holdings. Separately, Johnson & Johnson plans a new cell therapy manufacturing facility and faces a $250,000 talc powder lawsuit verdict, while analysts from RBC Capital and Morgan Stanley have increased their price targets for the stock.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Johnson & Johnson exec VP, CFO Wolk sells $21.7 million in stock
Johnson & Johnson’s Executive Vice President and CFO, Joseph J. Wolk, sold 84,654 shares of company stock for approximately $21.7 million and exercised options to acquire 66,475 shares. Following the transactions, Wolk directly owns 38,961 shares, with additional indirect holdings. Separately, Johnson & Johnson plans a new cell therapy manufacturing facility and faces a $250,000 talc powder lawsuit verdict, while analysts from RBC Capital and Morgan Stanley have increased their price targets for the stock.